A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Inclusion Criteria:
Diagnosis of HS for at least 6 months prior to screening visit.
Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:
Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.
Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period.
Further inclusion criteria apply.
Exclusion Criteria: